Literature DB >> 15952415

Autoimmune hepatitis during intravenous glucocorticoid pulse therapy for Graves' ophthalmopathy treated successfully with glucocorticoids themselves.

M Marinò1, E Morabito, M A Altea, E Ambrogini, F Oliveri, M R Brunetto, L E Pollina, D Campani, P Vitti, L Bartalena, A Pincheral, C Marcocci.   

Abstract

We report a case of acute hepatitis of autoimmune origin which occurred in a 43-yr-old woman during iv glucocorticoid (GC) pulse therapy for Graves' ophthalmopathy (GO). Prior to therapy, liver function tests were normal with no previous history of liver disorders or conditions predisposing to GC-associated liver damage. After the administration of a 4.7-g cumulative dose of methylprednisolone acetate, there was a marked increase of liver enzymes, prompting immediate discontinuation of iv GC. Nevertheless, liver enzymes increased further, reaching a peak 45 days later, with values 30- to 50-fold greater than those prior to therapy, associated with evidence of impaired liver function. Liver biopsy showed a marked lymphocytic infiltration, likely indicating an autoimmune hepatitis. Based on the assumption that following GC-induced immune suppression, autoimmune hepatitis might have been precipitated by sudden re-activation of the immune system during interpulse periods, we treated the patient with im and then oral GC, in order to re-induce immune suppression. Within three days from re-institution of GC therapy, there was a marked reduction of liver enzymes and amelioration of liver function. Complete normalization was achieved two months later, while the patient was still receiving a low maintenance dose of oral prednisone.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15952415     DOI: 10.1007/bf03345386

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  14 in total

1.  Subacute severe steatohepatitis during prednisolone therapy for systemic lupus erythematosis.

Authors:  T Nanki; R Koike; N Miyasaka
Journal:  Am J Gastroenterol       Date:  1999-11       Impact factor: 10.864

2.  Fatal liver failure after high-dose glucocorticoid pulse therapy in a patient with severe thyroid eye disease.

Authors:  M Weissel; W Hauff
Journal:  Thyroid       Date:  2000-06       Impact factor: 6.568

3.  Acute severe steatohepatitis related to prednisolone therapy.

Authors:  S P Dourakis; V A Sevastianos; P Kaliopi
Journal:  Am J Gastroenterol       Date:  2002-04       Impact factor: 10.864

4.  Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves' ophthalmopathy.

Authors:  Michele Marinó; Eugenia Morabito; Maurizia Rossana Brunetto; Luigi Bartalena; Aldo Pinchera; Claudio Marocci
Journal:  Thyroid       Date:  2004-05       Impact factor: 6.568

Review 5.  Novel aspects of immunosuppressive and radiotherapy management of Graves' ophthalmopathy.

Authors:  C Marcocci; M Marinò; R Rocchi; F Menconi; E Morabito; A Pinchera
Journal:  J Endocrinol Invest       Date:  2004-03       Impact factor: 4.256

6.  A prospective study of viral hepatitis A and the question of chronicity.

Authors:  G Lesnicar
Journal:  Hepatogastroenterology       Date:  1988-04

Review 7.  Management of Graves' ophthalmopathy: reality and perspectives.

Authors:  L Bartalena; A Pinchera; C Marcocci
Journal:  Endocr Rev       Date:  2000-04       Impact factor: 19.871

8.  Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study.

Authors:  C Marcocci; L Bartalena; M L Tanda; L Manetti; E Dell'Unto; R Rocchi; G Barbesino; B Mazzi; M P Bartolomei; P Lepri; F Cartei; M Nardi; A Pinchera
Journal:  J Clin Endocrinol Metab       Date:  2001-08       Impact factor: 5.958

Review 9.  Orbital radiotherapy for Graves' ophthalmopathy.

Authors:  Luigi Bartalena; Claudio Marcocci; Maria Laura Tanda; Roberto Rocchi; Barbara Mazzi; Giuseppe Barbesino; Aldo Pinchera
Journal:  Thyroid       Date:  2002-03       Impact factor: 6.568

10.  Autoantibodies and defined target autoantigens in autoimmune hepatitis: an overview.

Authors:  G N. Dalekos; K Zachou; C Liaskos; N Gatselis
Journal:  Eur J Intern Med       Date:  2002-08       Impact factor: 4.487

View more
  11 in total

Review 1.  An update on medical management of Graves' ophthalmopathy.

Authors:  L Bartalena; C Marcocci; M L Tanda; E Piantanida; A Lai; M Marinò; A Pinchera
Journal:  J Endocrinol Invest       Date:  2005-05       Impact factor: 4.256

2.  Quercetin decreases proliferation of orbital fibroblasts and their release of hyaluronic acid.

Authors:  S Lisi; R Botta; M Lemmi; S Sellari-Franceschini; M A Altea; E Sisti; G Casini; M Nardi; C Marcocci; A Pinchera; M Marinò
Journal:  J Endocrinol Invest       Date:  2010-10-27       Impact factor: 4.256

3.  Development of autoimmune hepatitis type 1 after pulsed methylprednisolone therapy for multiple sclerosis: a case report.

Authors:  Atsushi Takahashi; Yukiko Kanno; Yuta Takahashi; Natsumi Sakamoto; Kyoko Monoe; Hironobu Saito; Kazumichi Abe; Junko Yokokawa; Atsushi Irisawa; Hiromasa Ohira
Journal:  World J Gastroenterol       Date:  2008-09-21       Impact factor: 5.742

Review 4.  Acute liver damage following intravenous glucocorticoid treatment for Graves' ophthalmopathy.

Authors:  Mariacarla Moleti; Giuseppe Giuffrida; Giacomo Sturniolo; Giovanni Squadrito; Alfredo Campennì; Silvia Morelli; Efisio Puxeddu; Eleonora Sisti; Francesco Trimarchi; Francesco Vermiglio; Michele Marinò
Journal:  Endocrine       Date:  2016-03-22       Impact factor: 3.633

5.  Liver injury after methylprednisolone pulses: A disputable cause of hepatotoxicity. A case series and literature review.

Authors:  Miguel Eugenio Zoubek; José Pinazo-Bandera; Aida Ortega-Alonso; Nelia Hernández; Javier Crespo; Fernando Contreras; Inmaculada Medina-Cáliz; Judith Sanabria-Cabrera; Rocío Sanjuan-Jiménez; Andrés González-Jiménez; Miren García-Cortés; M Isabel Lucena; Raúl J Andrade; Mercedes Robles-Díaz
Journal:  United European Gastroenterol J       Date:  2019-03-24       Impact factor: 4.623

6.  Prospectively recorded and MedDRA-coded safety data of intravenous methylprednisolone therapy in Graves' orbitopathy.

Authors:  M Riedl; E Kolbe; E Kampmann; I Krämer; G J Kahaly
Journal:  J Endocrinol Invest       Date:  2015-01-10       Impact factor: 4.256

Review 7.  Recent Advances in the Histopathology of Drug-Induced Liver Injury.

Authors:  David E Kleiner
Journal:  Surg Pathol Clin       Date:  2018-06

8.  Statins are not a risk factor for liver damage associated with intravenous glucocorticoid pulse therapy for Graves' orbitopathy.

Authors:  E Sabini; E Sisti; B Coco; M Leo; I Ionni; F Menconi; M A Profilo; B Mazzi; R Rocchi; F Latrofa; P Vitti; M Brunetto; C Marcocci; M Marinò
Journal:  J Endocrinol Invest       Date:  2016-07-27       Impact factor: 4.256

9.  Influence of Methylprednisolone Pulse Therapy on Liver Function in Patients with Graves' Orbitopathy.

Authors:  Piotr Miśkiewicz; Anna Jankowska; Kinga Brodzińska; Justyna Milczarek-Banach; Urszula Ambroziak
Journal:  Int J Endocrinol       Date:  2018-10-21       Impact factor: 3.257

10.  Liver Dysfunction Associated with Intravenous Methylprednisolone Pulse Therapy in Patients with Graves' Orbitopathy.

Authors:  Hiroyuki Eguchi; Junichi Tani; Saori Hirao; Munehisa Tsuruta; Ichiro Tokubuchi; Kentaro Yamada; Masataka Kasaoka; Yasuo Teshima; Tatsuyuki Kakuma; Yuji Hiromatsu
Journal:  Int J Endocrinol       Date:  2015-06-28       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.